Axsome Therapeutics Files 8-K on Financial Condition
Ticker: AXSM · Form: 8-K · Filed: Feb 20, 2024 · CIK: 1579428
| Field | Detail |
|---|---|
| Company | Axsome Therapeutics, INC. (AXSM) |
| Form Type | 8-K |
| Filed Date | Feb 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, 8-K, corporate-filing
TL;DR
**Axsome Therapeutics just dropped an 8-K on its financials, standard stuff.**
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on February 20, 2024, to report on its results of operations and financial condition. The filing, under SEC File Number 001-37635, indicates that the company, based at One World Trade Center, 22nd Floor, New York, NY, is a pharmaceutical preparations firm incorporated in Delaware. This report is a standard disclosure for current events impacting the company's financial status.
Why It Matters
This filing provides a public update on Axsome Therapeutics' financial health, offering transparency to investors and the market regarding its operational performance.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial condition and does not indicate any immediate, specific risks.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- Delaware (company) — State of Incorporation
- New York (company) — Business Address City
- February 20, 2024 (date) — Date of Report
- 001-37635 (company) — Commission File Number
FAQ
What is the purpose of this 8-K filing by Axsome Therapeutics, Inc.?
The purpose of this 8-K filing is to report on the company's results of operations and financial condition, as indicated by the 'ITEM INFORMATION: Results of Operations and Financial Condition' section.
When was this 8-K report filed?
The report was filed on February 20, 2024, which is stated as the 'Date of Report (Date of earliest event reported): February 20, 2024'.
Where is Axsome Therapeutics, Inc.'s principal executive office located?
Axsome Therapeutics, Inc.'s principal executive office is located at One World Trade Center, 22nd Floor, New York, New York 10007.
What is the Commission File Number for Axsome Therapeutics, Inc.?
The Commission File Number for Axsome Therapeutics, Inc. is 001-37635.
What is the primary business classification of Axsome Therapeutics, Inc.?
Axsome Therapeutics, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]' according to its Standard Industrial Classification.
Filing Stats: 541 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-02-20 07:05:36
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20240220.htm (8-K) — 41KB
- axsm-ex99_1.htm (EX-99.1) — 228KB
- img36028404_0.jpg (GRAPHIC) — 22KB
- 0000950170-24-016797.txt ( ) — 423KB
- axsm-20240220.xsd (EX-101.SCH) — 23KB
- axsm-20240220_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On February 20, 2024, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and provided an update on the Company's operations. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information included in Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1 hereto), shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Exchange Act or Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated February 20, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: February 20, 2024 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer